Medical Device Licence Submission Content

1. Key takeaways

A Medical Device Licence (MDL) dossier that Health Canada will accept is built around four questions that must be answered clearly and completely. First, what the product is: the device description, its intended use, its classification and, just as importantly, the classification rationale that explains why that classification was reached. Second, why the device is safe and effective: the safety and effectiveness evidence submitted with the application, noting that Class III and Class IV applications must also include clinical effectiveness evidence. Third, how the quality management system safeguards the product in production and on the market: for Class II, III and IV devices this evidence takes the form of a valid MDSAP certificate. Fourth, how the labelling is presented: the labelling obligations set out in sections 21 to 23 of the Medical Devices Regulations. In addition to these four pillars, the dossier must include supporting evidence on the quality management system and on risk management.

• Device description, intended use, classification and classification rationale form the identity pillar of the dossier.
• Safety and effectiveness evidence is mandatory; Class III and IV applications additionally require clinical effectiveness evidence.
• For Class II to IV devices, the quality system evidence is a valid MDSAP certificate.
• Labelling must comply with sections 21 to 23 of the Medical Devices Regulations.
• Supporting evidence on the quality management system and risk management is submitted alongside the four pillars.

2. Legal basis

The table below consolidates the regulatory sources cited in this article. The Medical Devices Regulations provisions referenced here were verified against Justice Laws; the Health Canada content was verified against canada.ca. Where an item derives from industry compilation rather than an official source, it is identified as a practical estimate and readers should rely on the note at the end of this article for its standing.

3. Expert insights

Insight 1: the classification rationale belongs in the dossier, not just the classification result.

Classification is determined by the rules in Schedule 1 of the Medical Devices Regulations, and the dossier should state the specific rule numbers that apply together with the reasoning that led from those rules to the final class. A classification section that only states the result, without showing the applicable rule and the decision logic, leaves the reviewer unable to confirm the class from the dossier itself. Where the rationale is missing or the logic is unclear, Health Canada will ask for corrections at the screening stage, which delays the review and adds avoidable correspondence. Writing the rationale up front is therefore not a formality but a direct safeguard of review timelines. The same reasoning trail also helps later: when the device or its intended use changes, an existing, well documented rationale makes re-evaluation of the classification faster and more defensible.

Insight 2: clinical effectiveness evidence is the centre of gravity of Class III and Class IV dossiers.

Health Canada officially lists four accepted forms of clinical effectiveness evidence: clinical trials, clinical reviews, meta-analyses and reviews of real-world evidence. The choice among these forms is not arbitrary. The dossier should explain why the selected form matches the risk profile of the device, rather than simply attaching a literature list and leaving the reviewer to infer its relevance. A submission that pairs the chosen form with an explicit matching argument is easier to assess and less likely to generate deficiency requests. Preparing this section early, during the planning stage of the dossier, also gives the organisation time to gather or generate the evidence in the form it intends to rely on, instead of retrofitting the narrative around whatever material happens to be available at submission time.

Insight 3: the form of quality management system evidence is the MDSAP certificate, not a self-declaration (practical estimate).

MDSAP has been the audit programme recognised for Canada since 1 January 2019 (practical estimate). For Class II, III and IV applications, the quality management system evidence in the dossier should be presented as a valid MDSAP certificate. Two checks matter when assembling this element: the certificate must be valid across the expected application and review period, and the audit scope recorded on the certificate must include Canada. A certificate whose scope omits Canada does not serve as system evidence for a Canadian application, even if the certificate is otherwise current. Confirming both points before submission avoids one of the most avoidable grounds for a deficient application.

Insight 4: handling procedures on the import and distribution side are an explicit official requirement.

The official Health Canada page states that companies importing or distributing Class II, III or IV devices must establish procedures for storage, handling, delivery, installation and, where applicable, servicing. These procedures are held by the importer or distributor, not by the manufacturer, but the manufacturer cannot treat them as someone else’s problem. The dossier and the agreements with the Canadian counterpart should show how the manufacturer connects with these five categories of procedures: for example, how product information flows to the party responsible for storage conditions, and how the manufacturer is informed of issues that arise during delivery, installation or servicing. Demonstrating this linkage in the dossier shows the reviewer that the device will be handled appropriately throughout the Canadian supply chain, not only up to the moment it leaves the factory.

4. Practical recommendations

• Structure the dossier around the four-part framework: what the product is; why it is safe and effective; how the quality system safeguards it; how the labelling is presented.
• In the classification section, state the specific Schedule 1 rule numbers and the decision logic that leads from the rules to the assigned class.
• For Class III and IV devices, decide the form of clinical evidence during dossier planning and document the reasons why that form matches the device risk profile.
• Check that the MDSAP certificate remains valid and that its audit scope covers Canada throughout both the application and the review period.
• Reconcile with the Canadian importer how the five categories of procedures — handling, storage, delivery, installation and servicing — connect with the manufacturer’s own processes.

5. Verification checklist

• □ The device description and intended use are complete.
• □ The classification rationale states the Schedule 1 rule numbers and the decision logic.
• □ For Class III and IV, the clinical effectiveness evidence is complete and the reasons for the chosen form are documented.
• □ The MDSAP certificate is valid and its audit scope includes Canada.
• □ The labelling complies with sections 21 to 23 of the Regulations.
• □ The handling, storage, delivery, installation and servicing procedures of the importer have been reconciled with the manufacturer’s processes.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com